HCWB Stock Overview
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases.
HCW Biologics Inc. Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$2.24|
|52 Week High||US$7.05|
|52 Week Low||US$1.76|
|1 Month Change||-13.85%|
|3 Month Change||4.19%|
|1 Year Change||-38.96%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-64.44%|
Recent News & Updates
We Think HCW Biologics (NASDAQ:HCWB) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
|HCWB||US Biotechs||US Market|
Return vs Industry: HCWB underperformed the US Biotechs industry which returned -30% over the past year.
Return vs Market: HCWB underperformed the US Market which returned -23% over the past year.
|HCWB Average Weekly Movement||9.3%|
|Biotechs Industry Average Movement||11.1%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: HCWB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: HCWB's weekly volatility has decreased from 15% to 9% over the past year.
About the Company
HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company’s lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia.
HCW Biologics Inc. Fundamentals Summary
|HCWB fundamental statistics|
Is HCWB overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|HCWB income statement (TTM)|
|Cost of Revenue||US$1.62m|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.33|
|Net Profit Margin||-332.51%|
How did HCWB perform over the long term?See historical performance and comparison